Roche Holding AG
ROG
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Stocks News & Analysis
stocks
3 cheap Wide Moat stocks in a divided industry
All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far.
stocks
Obesity drug stocks: Where to invest now
Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
stocks
10 global stocks for a recession
These undervalued stocks come from high-quality companies in defensive sectors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,571.40 | 40.30 | -0.47% |
CAC 40 | 7,864.44 | 46.05 | -0.58% |
DAX 40 | 23,999.17 | 123.23 | -0.51% |
Dow JONES (US) | 41,925.72 | 65.28 | 0.16% |
FTSE 100 | 8,739.26 | 47.20 | -0.54% |
HKSE | 23,544.31 | 283.47 | -1.19% |
NASDAQ | 18,994.29 | 121.65 | 0.64% |
Nikkei 225 | 36,985.87 | 313.11 | -0.84% |
NZX 50 Index | 12,662.25 | 40.85 | -0.32% |
S&P 500 | 5,855.02 | 10.41 | 0.18% |
S&P/ASX 200 | 8,348.70 | 38.10 | -0.45% |
SSE Composite Index | 3,380.19 | 7.39 | -0.22% |